Article Menu

Export Article

More by Authors Links

Article Data

  • Views 2322
  • Dowloads 150

Original Research

Open Access

Prevalence of high risk human papillomavirus (HPV) infection and abnormal cervical cytology and knowledge about HPV vaccine in Eastern Turkey

  • H.G. Sahin1
  • A. Kolusari1,*,
  • H. Guducuoglu2

1Department of Obstetrics and Gynaecology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey

2Department of Microbiology and Clinical Microbiology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey

DOI: 10.12892/ejgo3477.2017 Vol.38,Issue 2,April 2017 pp.241-244

Published: 10 April 2017

*Corresponding Author(s): A. Kolusari E-mail: dralikolusari@yahoo.com

PDF (101.11 kB) View Full-text

Abstract

Purpose of investigation: The aim of the present study was to gather data on the high risk human papillomavirus (HPV) frequency and the distribution of HPV types in Eastern Turkey in relation to cervical cytology and to assess the knowledge about cervical cancer, HPV, and vaccination. Materials and Methods: The study population included 1,000 women aged between 20-65 years who attended the outpatients clinics of Department of Obstetrics and Gynecology of the Medical School of Yuzuncu Yıl University Hospital. Results: The overall prevalence of high risk HPV-DNA was 2.8 %. Abnormal cytology was observed in 12.9% of the cases. Abnormal cytology consisted of cervical cancer: 0.1%, LSIL: 1.6%, HSIL: 0.5%, ASC-H: 2.1%, atypical glandular cells: 0.4%, and ASCUS: 8.3 %. Conclusion: The prevalence of HPV was low in Eastern Turkey and the most common HPV types are similar to the literature. However, the prevalence of HPV infection is a growing problem worldwide and the awareness of the women in the region is limited.

Keywords

Human papillomavirus; Cervical cytological samples; Uterine cervical neoplasm; Turkey.

Cite and Share

H.g. Sahin, A. Kolusari, H. Guducuoglu. Prevalence of high risk human papillomavirus (HPV) infection and abnormal cervical cytology and knowledge about HPV vaccine in Eastern Turkey. European Journal of Gynaecological Oncology. 2017; 38(2): 241-244. doi: 10.12892/ejgo3477.2017

URL:

https://www.ejgo.net/articles/10.12892/ejgo3477.2017

References

[1] Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al.: “GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0. IARC CancerBase No. 11”. Lyon, France: International Agency for Research on Cancer. Available at: http://globocan.iarc.fr

[2] Nour N.M.: “Cervical cancer: a preventable death”. Rev. Obstet. Gynecol., 2009, 2, 240.

[3] The Nobel Prize in Physiology or Medicine 2008 [press release]. Stockholm, Sweden: The Nobel Assembly at Karolinska Institutet; October 6, 2008. Available at: http://nobelprize.org/nobel_prizes/medicine/laureates/2008/press.html

[4] Kjaer S.K., Breugelmans G., Munk C., Junge J., Watson M., Iftner T.: “Population based prevalence, type and age specific distribution of HPV in women before inroduction of an HPV vaccination program in Denmark”. Int. J. Cancer, 2008, 12, 1864.

[5] Bernard H.U., Burk R.D., Chen Z., van Doorslaer Kzur Hausen H., de Villers EM.: “Classification of papillomaviruses(PVs)based on 189 PV types and proposal of taxonomic amendments”. Virology, 2010, 401, 70.

[6] De Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al.: “Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study”. Lancet. Oncol., 2010, 11, 1048.

[7] Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S.,Winer R., et al.: “Human papillomavirus type distribution in invasive cervical cancer and high grade cervical lesions:A meta analysis update”. Int. J. Cancer, 2007, 121, 621.

[8] Ozyer S., Uzunlar O., Ozler S., Kaymak O., Baser E., Gungor T., et al.: “Awareness of Turkish female adolescents and young women about HPV and their attitudes towards HPV vaccination”. Asian Pac. J. Cancer Prev., 2013, 14, 4877.

[9] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[10] Dursun P., Ayhan A., Mutlu L., Çağlar M., Haberal A., Güngör T., et al.: “HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish Gynecologic Oncology Group centers”. Turk. Patoloji. Derg., 2013, 26, 210.

[11] Yuce K., Pinar A., Salman M.C., Alp A., Sayal B., Dogan S., et al.: “Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital based study”. Arch. Gynecol. Obstet., 2012, 286, 203.

[12] Dursun P., Senger S.S., Arslan H., Kuscu E., Ayhan A.: “Human papillomavirus prevalence and types among Turkish women at a gynecology outpatient unit”. BMC Infect. Dis., 2009, 9, 191.

[13] Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., et al.: “Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis”. Lancet, 2005, 366, 991.

[14] Turkish Cervical Cancer and Cervical Cytology Research Group: “Prevelance of cervical cytological abnormalities in Turkey”. Int. J. Gynaecol. Obstet., 2009, 106, 206.

[15] Berois N., Heard I., Fortb Z., Alonso R., Sica A., Moerzinger P., et al.: “Prevalence of type specific HPV infection in Uruguay”. J. Med. Virol., 2014, 86, 647.

[16] Tonguc E., Gungor T., Var T., Kavak E., Yucel M., Uzunlar O.: “Knowledge about HPV, relation between HPV and cervix cancer and acceptance of HPV vaccine in women in eastern region of Turkey”. J. Ggnecol. Oncol., 2013, 24, 7.

Submission Turnaround Time

Top